Cargando…
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized that the mutational status of bone marrow dysplastic cells and leukemic blasts, a...
Autores principales: | Simoes, Catia, Chillon, Maria-Carmen, Martínez-Cuadrón, David, Calasanz, Maria-José, Vridiales, María-Belén, Vazquez, Iria, Hernández-Ruano, Montserrat, Ariceta, Beñat, Aguirre-Ruiz, Paula, Burgos, Leire, Alignani, Diego, Sarvide, Sarai, Villar, Sara, Pierola, Ana Alfonso, Prosper, Felipe, Ayala, Rosa, Martínez-López, Joaquin, Bergua Burgues, Juan Miguel, Vives, Susana, Perez-Simon, Jose A., Garcia-Fortes, Maria, Bernal del Castillo, Teresa, Colorado, Mercedes, Olave, Mayte, Rodríguez-Gutiérrez, Juan I., Labrador, Jorge, González, Marcos, San-Miguel, Jesús F., Sanz, Miguel Ángel, Montesinos, Pau, Paiva, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811200/ https://www.ncbi.nlm.nih.gov/pubmed/36240453 http://dx.doi.org/10.1182/bloodadvances.2022008141 |
Ejemplares similares
-
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
por: Villar, Sara, et al.
Publicado: (2022) -
Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design
por: Aguilera-Diaz, Almudena, et al.
Publicado: (2020) -
S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
por: Montesinos, Pau, et al.
Publicado: (2023) -
P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023) -
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
por: Ayala, Rosa, et al.
Publicado: (2022)